|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010654,
umls-concept:C0031727,
umls-concept:C0085862,
umls-concept:C0205099,
umls-concept:C0205332,
umls-concept:C0243077,
umls-concept:C0378796,
umls-concept:C0599894,
umls-concept:C1152564,
umls-concept:C1299583,
umls-concept:C1414313,
umls-concept:C1514562,
umls-concept:C1549571,
umls-concept:C1554184,
umls-concept:C1608386,
umls-concept:C1709915,
umls-concept:C1880389,
umls-concept:C1883204,
umls-concept:C1883221
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-4-30
|
|
pubmed:abstractText |
A series of 4-dimethylamino-but-2-enoic acid [4-(3,6-dioxo-cyclohexa-1,4-dienylamino)-7-ethoxy-quinazolin-6-yl]-amide derivatives were prepared. These compounds have two independent reactive centers and were designed to function as dual irreversible inhibitors of the kinase domains of both Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) where each reactive center targets a different, non-conserved, cysteine residue located in the ATP binding pocket of these enzymes. The compounds contain a 6-(4-(dimethylamino) crotonamide) Michael acceptor group that targets Cys-773 in EGFR and a 4-(amino-[1,4]benzoquinone) moiety that targets Cys-1045 in VEGFR-2. In vitro studies indicated that most of these compounds are relatively potent inhibitors of each enzyme. These inhibitors were compared with reference compounds that lack one or both of the reactive centers. The relative dependence of the IC(50) values on the concentration of ATP used in the assays suggests that these compounds appear to function as irreversible inhibitors of each kinase.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0968-0896
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3635-48
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17416531-Adenosine Triphosphate,
pubmed-meshheading:17416531-Binding Sites,
pubmed-meshheading:17416531-Biological Assay,
pubmed-meshheading:17416531-Cells, Cultured,
pubmed-meshheading:17416531-Humans,
pubmed-meshheading:17416531-Inhibitory Concentration 50,
pubmed-meshheading:17416531-Models, Molecular,
pubmed-meshheading:17416531-Molecular Structure,
pubmed-meshheading:17416531-Protein Conformation,
pubmed-meshheading:17416531-Protein Kinase Inhibitors,
pubmed-meshheading:17416531-Quinazolines,
pubmed-meshheading:17416531-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17416531-Vascular Endothelial Growth Factor Receptor-2
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
|
|
pubmed:affiliation |
Chemical and Screening Sciences and Oncology Research, Wyeth Research, 401 N. Middletown Road, Pearl River, NY 10965, USA. wissnea@wyeth.com
|
|
pubmed:publicationType |
Journal Article
|
